RMC-6236 | pan-RAS inhibitor
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 1 mg | $45.00 | ||
| 5 mg | $125.00 |
RMC-6236 (2765081-21-6) is broad spectrum inhibitor of both mutant and wild-type KRAS, NRAS, and HRAS variants.1,2 It binds with high affinity to cyclophilin A (KD = 55 nM) creating a binary complex that has high affinity for the active state of KRAS (KD = 131 nM for G12V, 364 nM for G12D and 154 nM for wild type). Active in in vivo xenograft models of NSCLC, PDAC, colorectal cancer, gastric carcinoma, and ovarian adenocarcinoma.2
References/Citations:
- Holderfield et al. (2024), Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy; Nature 629 919
- Jiang et al. (2024), Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers; Cancer Discov. 14 994
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
RMC-6236 (2765081-21-6) is broad spectrum inhibitor of both mutant and wild-type KRAS, NRAS, and HRAS variants.1,2 It binds with high affinity to cyclophilin A (KD = 55 nM) creating a binary complex that has high affinity for the active state of KRAS (KD = 131 nM for G12V, 364 nM for G12D and 154 nM for wild type). Active in in vivo xenograft models of NSCLC, PDAC, colorectal cancer, gastric carcinoma, and ovarian adenocarcinoma.2
References/Citations:
- Holderfield et al. (2024), Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy; Nature 629 919
- Jiang et al. (2024), Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers; Cancer Discov. 14 994
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass